Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: MediciNova, Inc.

Market Cap 64.97M 56.65M 52.47M 49.11M 92.11M 6.13B 92.67M 622M 241M 3.02B 244M 239M 10.48B P/E 2026 *
-5.08x
P/E 2027 * -3.52x
Enterprise Value 64.97M 56.65M 52.47M 49.11M 92.11M 6.13B 92.67M 622M 241M 3.02B 244M 239M 10.48B EV / Sales 2026 *
146x
EV / Sales 2027 * 162x
Free-Float
97.13%
Yield 2026 *
-
Yield 2027 * -
06-08 MediciNova Receives Notice Of Allowance For New Patent Covering Use Of MN-166 In Combination With Anti-PD-1 Immune Checkpoint Inhibitor For Glioblastoma Treatment CI
06-08 MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer MT
05-26 MediciNova Announces Completion Of Last Patient Last Visit In The MN-001-NATG-202 Clinical Trial Of MN-001 CI
05-14 MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-16 HC Wainwright Initiates MediciNova at Buy With $10 Price Target MT
02-20 MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-30 MediciNova, Inc. Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access- Program Evaluating MN-166 in ALS Patients CI
12-30 MediciNova Inc enters $50 million equity distribution agreement with Lucid Capital Markets RE
12-18 MediciNova, Inc. Announces Completion of Patient Enrollment Evaluating MN-166 in the Prevention of Chemotherapy-Induced Peripheral Neuropathy CI
12-18 MediciNova Completes Enrollment in a Phase 2 Study of Colorectal Cancer Drug MT
12-08 MediciNova, Inc. Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 in ALS (COMBAT-ALS) in ALS Presented at the 36th International Symposium on ALS/MND CI
11-19 MediciNova, Inc. Appoints Dr. Christopher Breder, MD, Phd as Clinical and Regulatory Advisorand to Lead Scientific Advisory Board Upon Its Formation CI
11-12 MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
1 day-1.49%
1 week+3.12%
Current month-2.94%
1 month-5.04%
3 months-6.38%
6 months-8.97%
Current year+0.76%
1 week 1.22
Extreme 1.22
1.36
1 month 1.22
Extreme 1.22
1.45
Current year 1.22
Extreme 1.22
1.92
1 year 1.17
Extreme 1.168
1.96
3 years 1.12
Extreme 1.12
2.66
5 years 1.12
Extreme 1.12
5.09
10 years 1.12
Extreme 1.12
14.5
Manager TitleAgeSince
Chief Executive Officer 76 2005-07-31
Director of Finance/CFO 49 2022-06-15
Chief Tech/Sci/R&D Officer 60 2011-08-31
Director TitleAgeSince
Chairman 76 2000-09-25
Director/Board Member 60 2019-07-23
Director/Board Member 69 2004-08-31
Date Insider Type Main position Quantity % Market Cap.
01-15Free

Chief Executive Officer

450,000 0.9156%
01-15Free

Chief Technology Officer

350,000 0.7122%
25-06-16Free

Director

20,000 0.0408%
Change 5-day change 1-year change 3-year change Capi.($)
-1.49%+3.12%+3.94%-43.83% 64.97M
+1.44%-1.25%+63.52%+114.88% 54.44B
+4.60%+5.82%+56.35%+43.04% 45.8B
-1.44%+1.51%-12.94%-19.24% 22.98B
-2.69%-0.95%-3.68%+379.00% 20.76B
+3.22%+2.94%+24.02%-35.05% 16.25B
+0.58%+1.08%+16.73%-38.06% 15.34B
-1.01%-2.97%+27.42%+171.92% 13.05B
+3.07%+5.43%+21.37% - 12.37B
+4.95%+13.49%+121.11%+249.05% 12.47B
Average +1.12%+2.28%+31.78%+91.30% 21.35B
Weighted average by Cap. +1.63%+1.38%+39.55%+98.65%

Financials

2026 *2027 *
Net sales 444K 387K 358K 335K 629K 41.85M 633K 4.25M 1.65M 20.6M 1.66M 1.63M 71.52M 400K 349K 323K 302K 567K 37.74M 571K 3.83M 1.49M 18.58M 1.5M 1.47M 64.51M
Net income -13.5M -11.77M -10.9M -10.21M -19.14M -1.27B -19.26M -129M -50.13M -627M -50.68M -49.6M -2.18B -22.14M -19.3M -17.88M -16.74M -31.39M -2.09B -31.58M -212M -82.2M -1.03B -83.11M -81.33M -3.57B
Net Debt - -
Logo MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Employees
6
Date Price Change Volume
26-06-18 1.320 $ -1.49% 34,840
26-06-17 1.340 $ +2.29% 17,384
26-06-16 1.310 $ +4.80% 124,046
26-06-15 1.250 $ +1.63% 122,087
26-06-12 1.230 $ -3.91% 103,463
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.320USD
Average target price
9.000USD
Spread / Average Target
+581.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNOV Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!